AMG

AMGEN INC. DL-,0001

Stock XETRA – Stock Market Prices, News & Analysis

Entreprise biopharmaceutique américaine qui développe des thérapies innovantes dans le domaine de la biotechnologie, principalement pour les maladies graves.

€ 286.50
3.27 %

AMGEN INC. DL-,0001

286.50
3.27 %
AMG

Entreprise biopharmaceutique américaine qui développe des thérapies innovantes dans le domaine de la biotechnologie, principalement pour les maladies graves.

Price history of AMGEN INC. DL-,0001
Price history of AMGEN INC. DL-,0001

Performance & Momentum

6 Months 19.40 %
1 Year 22.04 %
3 Years 50.95 %
5 Years

Strategic Analysis

AMGEN INC. DL-,0001 • 2026

Amgen Inc. positions itself as a major player in U.S. biotechnology, specializing in the development of innovative therapies targeting serious diseases. Its business model is built on strong innovation capabilities and deep medical research expertise, giving it a privileged position in high-value therapeutic segments.

Strengths
  • Diversified portfolio of innovative and differentiated biopharmaceutical treatments
  • Strong R&D expertise focused on serious diseases with high unmet medical needs
  • Positioning in a market experiencing sustained growth thanks to rising demand for advanced therapeutic solutions
Weaknesses
  • Dependence on the success of new molecules under development
  • Intense competition from other biotech and pharmaceutical leaders in therapeutic innovation
Momentum

Amgen's momentum shows a favorable trend over the medium and long term, confirmed by recent sustained performance. This trend reflects investor confidence in the company's ability to capitalize on its innovations and strengthen its presence in strategic medical segments.

Similar stocks to AMGEN INC. DL-,0001

Was this page helpful?

Your feedback helps us improve our research.

Take control
of your investments

Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.

  • Real-time multi-portfolio tracking
  • AI analysis of your positions
  • Counter your cognitive biases
Anantys Invest on iPhone